ALPHAVAX REPORTS HIV VACCINE STUDY RESULTS

AlphaVax has presented results from a Phase I trial evaluating a prototype HIV vaccine incorporating the HIV gag gene made using the company's alphavaccine technology.

Preliminary analysis of the blinded data, assuming that the placebo recipients generated no immune response, suggests that the vaccine induced an antibody response to the HIV gag antigen in 100 percent of the recipients at the highest dose tested and in a majority of the recipients at a 10-fold lower dose. In addition, the vaccine was well-tolerated, and no vaccine-related safety issues were identified.

"While definitive conclusions must await completion and unblinding of the study, we are very encouraged by the immunogenicity and safety profile of this candidate vaccine," said Jeff Chulay, AlphaVax's chief medical officer.

AlphaVax is working with its partners to advance the multigene HIV vaccine, as well as alphavaccines against influenza, cytomegalovirus and other diseases.